Congress at a Glance
Scientific Programme
Satellite Programme
Maps of the Venue
Search in:
 Papers, Programme or All
 Please use only plain characters
 (e.g., e, o, c and not è, ö or ç)
 		 
   
  Author   or    Free text  
   
  Author list  

  Personal Planner:
  Create a new login and password click here
Nb. Only your Personal Planner login is valid!
  Username Password  
   
 
  


Track:
  Treatment track
  Clinical research track
  Interface track
  Preclinical track
  Educational updates track

 
Scientific Programme Track:
View last minute changes Last minute changes
Back to overview
12:00-14:00 , Tuesday, 02 September 2008
Poster session page: 1 2   

12:00-14:00
P.3.a:  Psychotic disorders and antipsychotics - Psychotic disorders (clinical)
Poster area

P.3.a.001  Schizophrenic patients with no cognitive deficits – presentation of cases  Paper: P.3.a.001
K. Krysta*, I. Krupka-Matuszczyk, M. Hyper-Ochalik, M. Sygut, J. Przybylo, A. Klasik, Poland
 

P.3.a.002  Relationship between cannabis use and depression in a first episode of non-affective psychosis sample.  Paper: P.3.a.002
T. Moreno-Calle*, J.M. Rodriguez-Sanchez, J.M. Pelayo-Teran, R. Perez-Iglesias, J. Mayoral-vanSon, O. Martinez-Garcia, I. Mata, J.L. Vazquez-Barquero, B. Crespo-Facorro, Spain
 

P.3.a.003  Insight and outcome in schizophrenia patients  Paper: P.3.a.003
S.B. Baek*, S.J. Yang, W. Choi, South-Korea
 

P.3.a.004  Aggressive behaviour during acute mania: a cross-sectional study with 173 different manic patients  Paper: P.3.a.004
A. González-Pinto*, S. Ruiz de Azúa, A. Ugarte, I. González, M. Arrasate, K. Haidar, E. Echeburua, Spain
 

P.3.a.005  Predictive factors for therapeutic response in first episode psychosis  Paper: P.3.a.005
A. Baloescu*, G. Grigorescu, M.D. Gheorghe, Romania
 

P.3.a.006  The effects of BDNF-COMT gene interaction on symptoms and working memory in patient with schizophrenia  Paper: P.3.a.006
D.H. Han*, D.B. Park, S.Y. Joo, H.C. Shin, Y.S. Lee, K.J. Min, South-Korea
 

P.3.a.007  FOXP2 gene possibly associated with Korean schizophrenic patients  Paper: P.3.a.007
S.M. Jung*, B.J. Jung, J.S. Cho, J.M. Park, South-Korea
 

View last minute changes
P.3.a.008  Dysfunction of autonomic nervous system activity in schizophrenia and the influence of neuroleptics  Paper: P.3.a.008
I. Kishida*, M. Fujibayashi, S. Tanaka, C. Ishii, N. Ishii, T. Kimura, T. Moritani, Japan
Withdrawn
 

View last minute changes
P.3.a.009  Adjunctive estrogen treatment in women with chronic schizophrenia admitted in Hejazi and Ibn-e-Sina Paper: P.3.a.009
F. Behdani*, P. Hebrani, M. Mohamad nejad, Iran
Withdrawn
 

P.3.a.010  Continued loss of gray matter in chronic treatment-resistant schizophrenia  Paper: P.3.a.010
S. Mitelman*, E. Canfield, J. Schneiderman, L. Shihabuddin, M.S. Buchsbaum, USA
 

P.3.a.011  Facial emotion recognition in schizophrenic patients  Paper: P.3.a.011
S. Choi*, C. Shin, Y. Kim, S. Jeong, South-Korea
 

P.3.a.012  First episode schizophrenia: neurological soft signs and their relationship to one-year outcome  Paper: P.3.a.012
H. Kucerova*, R. Prikryl, L. Ustohal, E. Ceskova, Czech Republic
 

P.3.a.013  The effect of depression and anxiety symptoms on the results of combined dexamethasone/ corticotrophine releasing hormone test in schizophrenia  Paper: P.3.a.013
S.I. Lee*, B.J. Han, S.M. Hong, C.J. Shin, J.W. Son, S.K. Kim, South-Korea
 

P.3.a.014  Assessing remission in schizophrenia patients treated with long-acting risperidone in clinical practice  Paper: P.3.a.014
J. Peuskens, I. Tuma, J. Pecenak, L. Eriksson, B. Bork, M. Povey, A. Jacobs, K. Trakas, Z. Zhao*, USA
 

P.3.a.015  Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia  Paper: P.3.a.015
H. Detke*, D. McDonnell, J. Kane, D. Naber, G. Sethuraman, D. Lin, USA
 

P.3.a.016  Depressive dimension in acute schizophrenic inpatients and its impact on clinical outcome  Paper: P.3.a.016
M.C. Mauri, A. Colasanti*, A. Mazzocchi, F. Pellegrino, D. Moliterno, M. Rossattini, A.C. Altamura, Italy
 

P.3.a.017  Decreased serum proBDNF/BDNF ratio in patients with schizophrenia  Paper: P.3.a.017
D. Carlino*, E. Leone, E. Tongiorgi, M. De Vanna, Italy
 

P.3.a.018  Changes in antisaccadic test, gain and negative symptoms in schizophrenic patients treated with glycine  Paper: P.3.a.018
D. Strzelecki*, J. Rabe-Jablonska, Poland
 

P.3.a.019  Clinical experience of use of risperidone long acting injection in forensic patients in a high secure hospital  Paper: P.3.a.019
M. Das*, T. Maden, T. McKinnon, K. Das, J. Wakelam, United Kingdom
 

P.3.a.020  Serum trace elements and glucose 6 phosphate dehydrogenase activity level in schizophrenia  Paper: P.3.a.020
B. Kaya, N. Akdao, E. Fadyllyoolu, S. Unal, A. Sayal, H. Erdooan*, M.H. Emre, Turkey
 

P.3.a.301  Catatonia and acute confusional episodes in psychosis
Isabel Ganhao*, Portugal
 

P.3.a.302  Serum lipid profiles and schizophrenia: ratio of LDL/HDL cholesterol as predict factor for acute phase schizophrenia
V. Slavkovic*, S.M. Tosic Golubovic, J.N. Nikolic Popovic, N. Djordjevic, D. Gugleta, S. Manojlovic, D. Lazarevic, Serbia
 

12:00-14:00
P.3.b:  Psychotic disorders and antipsychotics - Psychotic disorders (basic)
Poster area

P.3.b.001  Clinical improvement in schizophrienia is associated with a normalization of elevated serum S100B and increased sRAGE  Paper: P.3.b.001
J. Steiner*, H.G. Bernstein, B. Bogerts, M.T. Wunderlich, G. Keilhoff, Germany
 

P.3.b.002  Isolation rearing-induced cognitive deficits involves opposing NMDA/D1 receptor changes in rat frontal cortex  Paper: P.3.b.002
B. Harvey*, C. Toua, L. Trabace, L. Brand, South Africa
 

P.3.b.003  Neurological soft signs in paranoid disorder and schizophrenia  Paper: P.3.b.003
S. Yesilyurt*, M.E. Ceylan, F. Maner, J. Güler, A. Turkcan, N. Satmis, Turkey
 

P.3.b.004  Agmatine induces schizophrenia-like symptom in Wistar rats  Paper: P.3.b.004
I.T. Uzbay*, H. Kayir, G. Göktalay, M. Yildirim, Turkey
 

P.3.b.005  Cannabis use and short-term evolution of homovanillic acid levels in patients with first episode schizophrenia  Paper: P.3.b.005
I. Baeza Pertegaz*, J. Castro-Fornieles, R. Deulofeu, E. de la Serna, J. Goti, M. Bernardo, Spain
 

P.3.b.006  A proton magnetic resonance spectroscopy study of the brain metabolite changes after antipsychotic treatment  Paper: P.3.b.006
A. Szulc*, B. Galinska, E. Tarasow, W. Dzienis, B. Kubas, B. Konarzewska, N. Waszkiewicz, A. Czernikiewicz, J. Walecki, Poland
 

P.3.b.007  Antioxidant enzyme activities and glutathione levels in unaffected relatives of patients with schizophrenia  Paper: P.3.b.007
A. Mechri*, L. Ben Othman, C. Fendri, M. Rafaa, L. Gaha, A. Kerkeni, Tunesian Republic
 

View last minute changes
P.3.b.008  Ser9Gly variant of dopamine D3 receptor gene associated with functioning and age at onset in females but not males with schizophrenia  Paper: P.3.b.008
B.R. Godlewska*, L. Olajossy-Hilkesberger, H. Marmurowska-Michalowska, J. Landowski, Poland
Withdrawn
 

P.3.b.009  Association study of STAT6 polymorphism with schizophrenia and periodic psychosis  Paper: P.3.b.009
S. Kawashige*, T. Kanazawa, A. Tsutsumi, M. Nishiguchi, A. Hokyo, H. Kikuyama, J. Koh, H. Yoneda, Japan
 

P.3.b.010  Markers of oxidative stress in patients with schizophrenia and metabolic syndrome. Preliminary study  Paper: P.3.b.010
B. Nemes*, M. Dronca, S.P. Pasca, D. Cozman, Romania
 

P.3.b.011  QTc interval in a sample of chronic schizophrenic inpatients  Paper: P.3.b.011
E. Paz-Silva, R. Ramos-Ríos*, M. Arrojo-Romero, J.L. Bouzón-Barreiro, J. Seoane-Prado, R. Codesido-Barcala, F. Carballal-Calvo, A. Crespí-Armenteros, R. Fernández-Pérez, I. Tortajada-Bonaselt, Spain
 

P.3.b.012  Gamma band response during auditory information processing in schizophrenia  Paper: P.3.b.012
G. Csifcsák*, E.A. Garab, I. Szendi, Z. Janka, Hungary
 

P.3.b.301  Decreased glutathione levels and antioxidant enzymes activities in treated and untreated patients with schizophrenia
A. Mechri*, M. Rafaa*, L. Ben Othman, C. Fendri, L. Gaha, A. Kerkeni, Tunesian Republic
 

12:00-14:00
P.3.c:  Psychotic disorders and antipsychotics - Antipsychotics (clinical)
Poster area

P.3.c.001  Outcome of the sertindole cohort prospective (SCoP) study: all-cause mortality  Paper: P.3.c.001
J. Peuskens*, SCoP Study Group, Belgium
 

P.3.c.002  Prevalence of lower urinary tract symptoms in the patients treated with clozapine  Paper: P.3.c.002
I.W. Chung*, S.H. Jeong, South-Korea
 

P.3.c.003  Risperidone in treatment of delusional disorders  Paper: P.3.c.003
N. Zivkovic*, G. Djokic, I. Stasevic Karlicic, M. Stasevic, Serbia
 

P.3.c.004  Effects of drd3 and dat gene polymorphisms on schizophrenia and response to olanzapine  Paper: P.3.c.004
C. Sengul*, M.E. Erdal, N. Aydin, F. Karadag, O.I. Ay, M.C. Balci Sengul, S. Aynacioglu, H. Herken, Turkey
 

P.3.c.005  Prolactin variations during screening for hyperprolactinaemia in patients taking antipsychotic medication  Paper: P.3.c.005
D. Yeomans*, United Kingdom
 

P.3.c.006  Cognitive function and antipsychotic treatment in chronic schizophrenia  Paper: P.3.c.006
A. Kalwa*, M. Rzewuska, A. Borkowska, A. Pirog-Balcerzak, M. Luks, J. Skalska, Poland
 

P.3.c.007  Olanzapine ameliorates psychotic excitement in schizophrenics influencing catecholamine metabolites, cytokines, and BDNF  Paper: P.3.c.007
J. Nakamura*, R. Yoshimura, N. Ueda, H. Hori, Japan
 

P.3.c.008  Open-label over effectiveness of long-acting risperidone as maintenance therapy of bipolar and schizoaffective disorders  Paper: P.3.c.008
P. Castro-Loli*, A. Benabarre, A. Martinez-Aran, J. Sanchez-Moreno, M. Salamero, A. Murru, E. Vieta, Spain
 

P.3.c.009  Effectiveness of a long-acting risperidone and psychosocial intervention for relapse prevention in schizophrenia.  Paper: P.3.c.009
T.K. Choi*, J.H. Kim, T.Y. Kim, S.H. Lee, South-Korea
 

P.3.c.010  Incidence of diabetes in atypical antipsychotic users differs according to agent: multisite epidemiologic study results  Paper: P.3.c.010
M. Ulcickas Yood*, G. deLorenze, C. Quesenberry Jr., G. L'Italien, S. Oliveria, A. Tsai, V. Willey, R. McQuade, J. Newcomer, USA
 

P.3.c.011  A double-blind dose-response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia  Paper: P.3.c.011
H. Ono*, S. Fujikoshi, T. Oka, M. Sugiura, M. Takahashi, Japan
 

P.3.c.012  Metabolic syndrome among patients with psychotic disorders treated with clozapine  Paper: P.3.c.012
F.M.M.A. van der Heijden*, P.M.J. Steylen, J.D.H. Kok, S. Tuinier, W.M.A. Verhoeven, The Netherlands
 

P.3.c.013  Risperidone long acting injection: 2 year outcomes in a naturalistic study  Paper: P.3.c.013
P. Deslandes*, A. Thomas, A. Lewis, R.D.E. Sewell, United Kingdom
 

View last minute changes
P.3.c.014  The impact of risperidone long acting injection on the 6-12 months outcome in patients suffering from psychosis  Paper: P.3.c.014
R. Gupta*, A. Chitewe, F. Roehricht, R. Bottlender, United Kingdom
Withdrawn
 

View last minute changes
P.3.c.015  Effects of treatment with antipsychotic medications on thyroid hormone concentrations  Paper: P.3.c.015
R. Bunevicius*, V. Steibliene, N. Mickuviene, Lithuania
R. Bunevicius* will be replaced by V. Steibliene
 

P.3.c.016  Predictors of response to antipsychotics and/or associations in schizoaffective disorder  Paper: P.3.c.016
A. Chirita*, O. Panait, Romania
 

P.3.c.017  Impact of psychoeducation and drug side effects on inpatient psychiatric satisfaction with schizophrenic patients  Paper: P.3.c.017
C.K. Kim*, J.H. Jang, South-Korea
 

P.3.c.018  Clinical improvement and metabolic effects of antipsychotic drugs in schizophrenia  Paper: P.3.c.018
K. Olszewska*, J. Rybakowski, Poland
 

P.3.c.019  Psychiatrists' attitudes to antipsychotic depot injections (N=102): changes over 5 years  Paper: P.3.c.019
M.X. Patel*, I.B. Chaudhry, N. Husain, S. McLaughlin, P. Cunningham, A.S. David, P.M. Haddad, United Kingdom
 

P.3.c.020  Psychiatrists' attitudes to antipsychotic depot injections (N=102): preferences and choice  Paper: P.3.c.020
P.M. Haddad*, I.B. Chaudhry, N. Husain, S. McLaughlin, P. Cunningham, A.S. David, M.X. Patel, United Kingdom
 

P.3.c.021  Is there any difference of incidence of the restless leg syndrome between antipsychotics?  Paper: P.3.c.021
I.K. Sohn*, I.Y. Kim, W. Hahm, K.H. Cheong, South-Korea
 

P.3.c.022  Analyses of genetic factors in olanzapine-induced weight gain in schizophrenic patients  Paper: P.3.c.022
H. Ujike*, A. Nomura, Y. Morita, Y. Okahisa, T. Kotaka, M. Kodama, T. Ishiahara, S. Kuroda, Japan
 

P.3.c.023  Cannabidiol for the treatment of psychosis in Parkinson’s disease.  Paper: P.3.c.023
A.W. Zuardi*, J.A.S. Crippa, J.E.C. Hallak, J.P. Pinto, M.H.N. Chagas, G.G.R. Rodrigues, S.M. Dursun, V. Tumas, Brazil
 

P.3.c.025  Safe reintroduction of clozapine: changing trends  Paper: P.3.c.025
C. Franco*, A. Pons, E. Parellada, J.M. Goikolea, Spain
 

P.3.c.026  The questionnaire of the usage of depot injection in Japan  Paper: P.3.c.026
T. Kanazawa*, A. Tsutsumi, Y. Nishimoto, H. Yoneda, Japan
 

P.3.c.027  Metabolic syndrome,cardiovascular risk and antipsychotic treatment in schizophrenic patients  Paper: P.3.c.027
J. Castaño*, B. Diaz, C. Garnier, R. Sanchis, A. Horta, A. Navarro, R. Navines, L.M. Martin, A. Bulbena, Spain
 

P.3.c.028  A pharmacogenetic investigation of risperidone and perospirone - report from kansai multicenter study  Paper: P.3.c.028
T. Atsushi*, K. Tetsufumi, O. Gaku, M. Toshio, M. Naoki, S. Kazuhiro, K. Toshifumi, Y. Hiroshi, K. Toshihiko, Japan
 

P.3.c.029  Incidence of tardive dyskinesia in patients receiving first or second generation antipsychotic therapy  Paper: P.3.c.029
A. Tapp*, A. Wood, N. Kilzieh, L. Martin, A. Kennedy, M. Raskind, USA
 

P.3.c.030  Efficacy of atypicals comparing with clasical antipsychotics in first year treatment of first episode psychosis  Paper: P.3.c.030
M.D. Gheorghe*, A. Baloescu, G. Grigorescu, Romania
 

P.3.c.031  Evolution of psychotic inpatients treated with long-acting injectable risperidone after 1000 days of follow-up.  Paper: P.3.c.031
E. Nieto*, L. Villar, J. Fernández, C. Hernández, E. Román, P. Bonet, Spain
 

P.3.c.032  Monotherapy with amisulpride in an acute hospitalization unit (clinical uses under indication and off-label)  Paper: P.3.c.032
M. Planella Sala*, J. Orta, M. Bañuelos, E. Garcia, M.J. Rodríguez, Spain
 

P.3.c.033  Adiponectin as a biomarker for metabolic syndrome among patients on atypical antipsychotics  Paper: P.3.c.033
Y.M. Bai*, J.Y. Chen, C.C. Lin, Y.W. Shiung, T.T. Chen, T.P. Su, Taiwan
 

P.3.c.034  Attitudes of patients and mental health staff to antipsychotic long acting (depot) injections – a systematic review  Paper: P.3.c.034
M. Taylor*, L. Waddell, United Kingdom
 

View last minute changes
P.3.c.035  Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics  Paper: P.3.c.035
S.W. Kim*, I.S. Shin, J.M. Kim, S.J. Yang, J.S. Yoon, J.H. Lee, K.H. Chung, J.A. Yoo, Y.H. Lee, South-Korea
S.W. Kim* will be replaced by J.H. Lee
 

P.3.c.036  Comparison of intramuscular olanzapine and haloperidol for the treatment of delirium  Paper: P.3.c.036
J.J. Kim*, H.K. Lim, C.U. Pae, C.U. Lee, C. Lee, I.H. Paik, South-Korea
 

P.3.c.037  An open study of the safety and efficacy of a novel antipsychotic (BL-1020) with reduced risk for extrapyramidal symptoms  Paper: P.3.c.037
R. Anand*, M. Davidson, Y. Geffen, D. Vasile, I. Dan, Switzerland
 

P.3.c.038  The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trial  Paper: P.3.c.038
P.J.A. van den Broek*, B. Penterman, J.W. Hummelen, R.J. Verkes, The Netherlands
 

P.3.c.039  Sexual dysfunction in patients with schizophrenia on antipsychotic medication  Paper: P.3.c.039
J. Castaño*, C. Garnier, F. Portillo, L. Gonzalez, R. Sanchis, B. Diaz, L.M. Martin, A. Bulbena, Spain
 

P.3.c.040  Risk of metabolic, cardiologic, and endocrinologic abnormalities in patients under long-term antipsychotic treatment  Paper: P.3.c.040
G. Cerveri*, P. Ala, L. Volonteri, I. Netti, C. Mencacci, Italy
 

P.3.c.041  Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis  Paper: P.3.c.041
N. Cruz*, J.M. Goikolea, J. Sanchez-Moreno, E. Vieta, Spain
 

P.3.c.042  Use of antipsychotics in psychiatric emergency departments. A prospective study from 2003 to 2006  Paper: P.3.c.042
C. Garnier*, J. Castaño, N. Espluga, J.M. Ginés, B. Díaz, L.M. Martín, A. Merino, A. Bulbena, Spain
 

P.3.c.043  Does the inclusion of rapid cyclers jeopardize the chance of a positive outcome in acute mania trials?  Paper: P.3.c.043
N. Cruz*, C.M. Bonnin, C. Franco, J.M. Goikolea, E. Vieta, Spain
 

P.3.c.044  Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients  Paper: P.3.c.044
A.F.Y. Al Hadithy, S.A. Ivanova, P. Pechlivanoglou, A. Semke, O. Fedorenko, E. Kornetova, L. Ryadovaya, J.R.B.J. Brouwers, R. Bruggeman, A.J.M. Loonen*, The Netherlands
 

View last minute changes
P.3.c.045  Management of expectations, satisfaction and well-being of psychotic patients, their families and caregivers (alliance)  Paper: P.3.c.045
M.F. Bravo Ortiz, J.R. Gutiérrez Casares, C. Meseguer, A. Rodríguez-Morales, D. Alonso-Escolano*, Spain
D. Alonso-Escolano* will be replaced by J.R. Gutiérrez Casares
 

P.3.c.046  Zuclopenthixol interactions with paroxetine,fluoxetine,carbamazepine & levomepromazine in routine therapeutic monitoring  Paper: P.3.c.046
S.J.C. Davies*, A.A. Westin, I. Castberg, G. Lewis, M.S. Lennard, O. Spigset, United Kingdom
 

P.3.c.047  The influence of the CYP2D6 polymorphism on the clinical response to aripiprazole in patients with schizophrenia  Paper: P.3.c.047
H. Park*, E. Kim, D. Kang, J. Choi, K. Yoo, I. Jang, S. Shin, J. Kwon, South-Korea
 

P.3.c.048  Evolution of neuroleptic-induced extrapyramidal syndromes in Spain  Paper: P.3.c.048
O. Gonzalez Irizar*, S. Arranz, I. Grau, C. Garcia-Ribera, A. Bulbena, A. Labad, Spain
 

P.3.c.049  Case series on the use of aripiprazole for tic disorder  Paper: P.3.c.049
B. Semerci*, A.S.L.I. Soyer, Turkey
 

View last minute changes
P.3.c.050  Attitudes of psychiatrists toward long-acting injectable antipsychotic  Paper: P.3.c.050
G. Yun, Y. Kim, E. Kim, W. Lim, S. Bae, S. Kim, H. Park*, South-Korea
Withdrawn
 

P.3.c.051  Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers  Paper: P.3.c.051
M. Kapás*, G. Pásztor Mészáros, B. Yu, J. Shi, B. Knoche, I. Laszlovszky, G. Bolton, Hungary
 

P.3.c.052  Risperidone long-acting injection in the treatment of recently versus longer diagnosed patients with schizophrenia  Paper: P.3.c.052
T. Lambert, J.M. Olivares, I. Tuma, J. Peuskens, J. Pecenak, H. bij de Weg, L. Eriksson, B. Bork, M. Povey, Z. Zhao*, Australia
 

P.3.c.053  Do early changes in triglycerides predict later changes during olanzapine treatment?  Paper: P.3.c.053
V. Poole-Hoffmann*, M.G. Case, V.L. Stauffer, J. Jacobson, R. Conley, USA
 

P.3.c.054  Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data  Paper: P.3.c.054
H. Detke*, D. McDonnell, S. Andersen, S. Watson, USA
 

P.3.c.055  The incidence of metabolic syndrome and its reversibility in patients with psychotic disorders followed for one year  Paper: P.3.c.055
S. Schorr*, C.J. Slooff, R. Bruggeman, K. Taxis, The Netherlands
 

P.3.c.056  Dose selection of asenapine: application of models based on D2 occupancy to predict efficacy and safety  Paper: P.3.c.056
R. de Greef*, A. Maloney, P. Olsson-Gisleskog, K. Prins, J. Schoemaker, J. Panagides, The Netherlands
 

View last minute changes
P.3.c.057  An evaluation of the clinical value of aripiprazole in the treatment of mania  Paper: P.3.c.057
J.M. Donoghue*, United Kingdom
Withdrawn
 

P.3.c.058  Interim-analysis of a long-term treatment study with long-acting injectable risperidone and oral second generation antipsychotics in schizophrenia  Paper: P.3.c.058
B. Ibach*, A. Schreiner, Germany
 

P.3.c.059  Post-injection delirium/sedation syndrome observed with olanzapine long-acting injection: review of the first 25 events  Paper: P.3.c.059
D. McDonnell*, S. Sorsaburu, E. Brunner, H. Detke, S. Andersen, R. Bergstrom, M. Mitchell, K. Ogle, S. Watson, S. Corya, USA
 

P.3.c.060  Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia  Paper: P.3.c.060
B. Kinon*, L. Chen, V.L. Stauffer, H. Ascher-Svanum, W. Zhou, O. Tomori, S. Kollack-Walker, J.M. Kane, S. Kapur, USA
 

P.3.c.061  Neuroleptic malignant syndrome after abrupt withdrawal of anticholinergic agents: case report  Paper: P.3.c.061
K. Kosma*, B. Roumbos, M. Mamali, K. Xipas, A. Fortos, Greece
 

P.3.c.062  32 weeks follow-up of effectiveness of schizophrenia treatment with olanzapine  Paper: P.3.c.062
M. Krzystanek*, I. Krupka-Matuszczyk, Poland
 

P.3.c.063  Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia  Paper: P.3.c.063
T. Lan*, H. Chiu, T. Hu, H. Huang, B. Wu, Y. Tuan, Taiwan
 

P.3.c.064  Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome  Paper: P.3.c.064
J. Larsen*, M. Holdrup, B. Christensen, C. Sigalin, P.M. Nilsson, S. Kolb, Denmark
 

View last minute changes
P.3.c.065  Metanalysis of medical and non medial treatments of the prodromal phase of psychotic illness, the socalled at risk mental states  Paper: P.3.c.065
M. Agius*, C. Kelly, R. Zaman, United Kingdom
M. Agius* will be replaced by R. Zaman
 

P.3.c.066  Adjunctive long-acting risperidone delays mood episode relapse in patients with frequently relapsing bipolar disorder  Paper: P.3.c.066
L. Alphs*, J.T. Haskins, I. Turkoz, N. Turner, A. Schreiner, W. Macfadden, USA
 

P.3.c.067  Replicated genetic association study of dopamine receptor D2 gene variants and serum prolactin increase  Paper: P.3.c.067
J. Houston*, B. Fijal, D.H. Adams, USA
 

P.3.c.068  Olanzapine orodispersible vs haloperidol both associated with lorazepam in the treatment of agitation  Paper: P.3.c.068
V. Mantua*, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Issac, C. Sweeney, J. Komeh, A. Shaw, P. Rucci, R.W. Kerwin, United Kingdom
 

P.3.c.069  Day 4 partial response to ziprasidone predicts later treatment response in patients with bipolar disorder  Paper: P.3.c.069
E. Pappadopulos*, E. Vieta, F. Mandel, USA
 

P.3.c.070  Metabolic disorders in patients with schizophrenia treated by antipsychotic drugs in Europe: the METEOR study  Paper: P.3.c.070
M. Mauri, B. Falissard, M. De Hert*, K. Shaw, T. Wetterling, Belgium
 

P.3.c.071  Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study  Paper: P.3.c.071
M. De Hert*, B. Falissard, M. Mauri, K. Shaw, T. Wetterling, Belgium
 

P.3.c.072  Polymorphisms of the 5HT2A and D2 receptor genes and weight change during olanzapine treatment  Paper: P.3.c.072
L. Olajossy-Hilkesberger*, B. Godlewska, A. Tylec, M. Olajossy, H. Marmurowska-Michalowska, Austria
 

P.3.c.073  Cabergoline in the management of prolactine-induced symptoms in patients treated with atypical neuroleptics  Paper: P.3.c.073
J. Cobo*, R. Coronas, O. Jiménez-Palop, M. Pérez, R. Mas, L. Ros, G. García-Parés, Spain
 

P.3.c.074  Aripiprazole switch-on in chronic schizophrenia with atypical antipsychotics associated weight gain  Paper: P.3.c.074
D. Vasiliu*, O. Vasiliu, C. Tudor, D. Ungureanu, O. Cretu, M. Terpan, Romania
 

P.3.c.075  A 46-week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania (CN138-134)  Paper: P.3.c.075
E. Vieta*, C. Baudelet, R.D. McQuade, R.N. Marcus, R. Sanchez, Spain
 

P.3.c.076  Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine  Paper: P.3.c.076
W. Fleischhacker*, M.E. Heikkinen, J.P. Olie, P. Dewaele, R. McQuade, D. Hennicken, W. Kerselaers, W. Landsberg, Austria
 

P.3.c.077  Evaluation of the effectiveness and effect on cognitive functioning of aripiprazole in a range of schizophrenia patients  Paper: P.3.c.077
J. Peuskens*, A. de Patoul, W. Kerselaers, V. Halkin, Belgium
 

P.3.c.301  Fatal neuroleptic malignant syndrome due to amisulpride
I. Velikonja*, T. Furst-Koren, S. Vitorovic, Slovenia
 

P.3.c.302  Atypical antipsychotics side effects-risk factor for noncompliance in first episode psychosis
M.D. Gheorghe*, R. Grigorescu, A. Baloescu, Romania
 

View last minute changes
P.3.c.303  Effectiveness of conventional and atypical antipsychotics in chronic daily headache
N. Kouroumalos*, V. Nikolopoulos, Greece
Withdrawn
 

P.3.c.304  Ziprasidone versus olanzapine in recent-onset schizophrenia; results of an 8-week randomised controlled trial
K.P. Grootens*, N.M.J. Van Veelen, R.J. Verkes, R.S. Kahn, The Netherlands
 

P.3.c.305  Open randomized study of olanzapine and long-acting risperidone of long-term treatment in schizophrenia patients
A.V. Potapov*, E.E. Tsukarzi, S.N. Mosolov, Russia
 

P.3.c.306  The effects of adjunctive carbamiazepine or valproate on hostility and impulsivity among patients with schizophrenia
S. Tosic Golubovic*, V.S. Slavkovic, N.G. Nikolic, D.N. Djordjevic, D.G. Gugleta, Serbia
 

P.3.c.307  Clozapine – aripiprazole combination in treatment – resistant schizophrenia. Case report
G. Marian*, B.E. Ionescu, D. Ghinea, E.A. Nica, Romania
 

P.3.c.308  The predictive value of extrapyramidal symptoms induced by first generation antipsychotics in schizophrenia
D. Marinescu*, T. Udristoiu, I. Udristoiu, I. Marinescu, A. Chimorgiachis, M. Pirlog, Romania
 

P.3.c.309  Sexual dysfunction in patients treated with antipsychotics or mood stabilizers
M.C. Garcia Mahia*, M. Vidal Millares, C. Armas Barbazan, I. Veiga Ramos, Spain
 

P.3.c.310  Amisulpride efficacy in the management of psychosis in elderly patients
O. Vasiliu, M. Miclos, D. Vasile*, P. Ivanov, O. Cretu, Romania
 

P.3.c.311  Intramuscular ziprasidone efficiency in the acute treatment of bipolar disorder mixed episode
D. Vasiliu*, O. Vasiliu, Romania
 

P.3.c.312  Risperidone treatment of residual phenomenology in patients with long-term schizophrenic disorder
S. Hadzi-Angjelkovski*, N. Simonovski, G.J. Hadzi-Angjelkovski, L.J. Damjanovic, T. Novotni, V. Vujovic, V. Pejovska-Gerazova, Macedonia
 

12:00-14:00
P.3.d:  Psychotic disorders and antipsychotics - Antipsychotics (basic)
Poster area

P.3.d.001  SSR103800, an inhibitor of the GlyT-1 reverses hyperactivity in glutamatergic but not dopaminergic models in mice  Paper: P.3.d.001
D. Boulay*, O. Bergis, P. Avenet, G. Griebel, France
 

P.3.d.002  Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors  Paper: P.3.d.002
Y. Tadori*, A. Forbes, R. McQuade, T. Kikuchi, USA
 

P.3.d.003  Study investigating R231857 effects on scopolamine-induced CNS impairment in healthy men  Paper: P.3.d.003
M. Liem-Moolenaar*, P. De Boer, R.W.M. Zoethout, K. Franson, A.F. Cohen, J.M.A. Van Gerven, The Netherlands
 

P.3.d.004  1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) inhibits effects of MK-801 in rat frontal cortex: in vivo microdialysis study  Paper: P.3.d.004
A. Wasik*, K. Golembiowska, L. Antkiewicz-Michaluk, Poland
 

P.3.d.005  Differential effects of aripiprazole and haloperidol on GSK-3ß-mediated signal changes in SH-SY5Y cells  Paper: P.3.d.005
Y.H. Kim*, S.W. Park, H.Y. Cho, S.M. Choi, J.G. Lee, South-Korea
 

P.3.d.006  Effects of atypical antipsychotics on excitatory synaptic transmission, and dopamine and 5-HT levels in the hippocampus.  Paper: P.3.d.006
T. Kubota*, A. Ishikawa, T. Kawamura, M. Shou, X. Li, I. Jibiki, Japan
 

P.3.d.007  Monoamine receptors mediating clozapine and haloperidol action on glutamate and serotonin release in prefrontal cortex  Paper: P.3.d.007
J. López-Gil*, F. Artigas, A. Adell, Spain
 

P.3.d.008  Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition  Paper: P.3.d.008
P. Dogterom*, E. Hulskotte, M. Gerrits, C. Timmer, J.M. Ad Sitsen, H. de Greef, E. Spaans, P. Peeters, The Netherlands
 

P.3.d.009  Dopamine D1-D2 receptor interactions in the presence of antipsychotic drugs– in vitro studies  Paper: P.3.d.009
A. Faron-Górecka*, A. Górecki, M. Kusmider, K. Grymek, M. Dziedzicka-Wasylewska, Poland
 

P.3.d.010  Catabolic-anabolic balance and leucocytes's apoptosis in patients with schizophrenia  Paper: P.3.d.010
S. Ivanova*, N. Vyalova, A. Semke, Russia
 

P.3.d.011  Immunotropic effects of atypical neuroleptics olanzapine and amisulpride  Paper: P.3.d.011
O.A. Lobacheva*, T.P. Vetlugina, A.V. Semke, E.G. Kornetova, Russia
 

P.3.d.012  Can high dose related toxicity restrict the neuroprotective effect of risperidone and olanzapine: an experimental study?  Paper: P.3.d.012
B. Yulug, E. Ozan*, A.S. Gonul, N. Aydin, I. Kirpinar, Turkey
 

P.3.d.013  Off-label use of second generation antipsychotics in psychiatric inpatients: data from the AMSP study group  Paper: P.3.d.013
A. Konstantinidis*, A. Kutzelnigg, U. Moser, R. Grohmann, E. Jaquenoud Sirot, R. Engel, S. Kasper, Austria
 

P.3.d.014  Effects of cognitive enhancers and neuroleptics on novel object recognition test in neonatally PCP-treated mice  Paper: P.3.d.014
M. Morita*, J. Yarimizu, M. Aota, K. Harada, K. Ni, N. Matsuoka, Japan
 

P.3.d.015  Pharmacokinetics of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in rats and dogs  Paper: P.3.d.015
G. Pásztor Mészáros*, E. Terjéki Bolf, L. Gémesi, M. Kapás, K. Tihanyi, Z. Szombathelyi, Hungary
 

P.3.d.016  Effects of asenapine on prefrontal NMDA receptor-mediated transmission: involvement of dopamine D1 receptors  Paper: P.3.d.016
T.H. Svensson*, J. Gertow, M. Shahid, K. Jardemark, Sweden
 

P.3.d.017  Agonist-dependent internalization of 5-HT6 receptors visualized by immunofluorescence assay: blockade by antipsychotics  Paper: P.3.d.017
D.S. Dupuis*, M.J. Millan, A. Marcepoil, C. Mannoury la Cour, France
 

P.3.d.018  Effects of typical and atypical antipsychotic drugs on spatial learning and memory consolidation in normal rat  Paper: P.3.d.018
R. Faucard*, A. Kuzmin, E. Kuteeva, E. Elvander-Tottie, S.O. Ögren, Sweden
 

P.3.d.019  The influence of neuroleptic medication on several oxidative stress markers in schizophrenic patients  Paper: P.3.d.019
D. Cozman*, B. Nemes, C.E. Craciun, M. Dronca, Romania
 

P.3.d.020  Atypical neuroleptics may modify cortical oscillatory activity in schizophrenia  Paper: P.3.d.020
G. Mayner*, F. Ortuño, P. Lopez, M. Alegre, M. Valencia, J. Artieda, Spain
 

P.3.d.021  EGIS-11148: pharmacological characterization of a new atypical antipsychotic compound  Paper: P.3.d.021
G. Levay*, K. Moricz, H. Kompagne, S. Kertesz, J. Barkoczy, L. Harsing, I. Gacsalyi, Hungary
 

P.3.d.022  Asenapine-induced effects on cortical monoaminergic projections  Paper: P.3.d.022
M.M. Marcus, O. Frånberg, B. Schilström, C. Wiker, V. Ivanov, M. Shahid, T.H. Svensson*, Sweden
 

P.3.d.023  The effects of quetiapine and haloperidol on human plasma lipid peroxidation in vitro  Paper: P.3.d.023
A. Dietrich-Muszalska*, J. Rabe-Jablonska, B. Kontek, Poland
 

P.3.d.301  Antipsychotic polypharmacy: a survey of emergency and inpatient prescriptions in a psychiatric institution in Romania
A. Mihailescu*, S. Nastase, Romania
 

12:00-14:00
P.3.e:  Psychotic disorders and antipsychotics - Others (clinical)
Poster area

P.3.e.001  Impairments in understanding of irony and metaphor in schizophrenia  Paper: P.3.e.001
Y.T. Kim*, B.D. Lee, S.H. Joe, D.H. Kwon, South-Korea
 

P.3.e.002  Prognostic value of affective symptomatology in first-admitted psychotic patients: a three-year follow-up study  Paper: P.3.e.002
M. Arrasate*, A. González-Pinto, F. Mosquera, C. González, A. Aldama, B. Ibáñez, M. Gutiérrez, Spain
 

P.3.e.003  Predictors of abnormal involuntary movement in an African schizophrenia population  Paper: P.3.e.003
U.A. Botha*, D.J.H. Niehaus, S. Du Plessis, L. Koen, B.H. Lategan, L. Warnich, R.A. Emsley, South Africa
 

P.3.e.004  Neurological soft signs and frontal executive function in schizophrenics and their first degree relatives  Paper: P.3.e.004
I.S. Chee*, J.L. Kim, S.K. Wang, B.J. Hwang, South-Korea
 

P.3.e.005  Alert for metabolic abnormalities before initiating acute phase treatment of bipolar disorder  Paper: P.3.e.005
B. Kim*, S.U. Kim, H.J. Park, S.Y. Kim, H.S. Kim, Y.H. Joo, South-Korea
 

P.3.e.006  Efficiancy of risperidone in prevention of relapses in patients with schizophrenia  Paper: P.3.e.006
N. Cadikovska*, M. Jakovcevska-Kujundziska, V. Lazarova, O. Dimova, Macedonia
 

P.3.e.007  Polypharmacy: past or current psychiatric practice  Paper: P.3.e.007
V. Filovska*, J.M. Kujindziska, O. Dimova, Macedonia
 

P.3.e.008  Adjunctive topiramate in hospitalized patients with chronic schizophrenia disorder  Paper: P.3.e.008
P. Hebrani*, F. Behdani, A. Rafiee, Iran
 

P.3.e.009  Gender differences in schizophrenia: study a women's sample in treatment in the community  Paper: P.3.e.009
M. Zamarro*, D.C. Dolores Crespo, Spain
 

P.3.e.010  Perception of self-influence on the course of schizophrenia and adherence to antipsychotics  Paper: P.3.e.010
A. Kokoszka*, Poland
 

P.3.e.011  Psychotic disorders and risk for later cancer: a cohort study  Paper: P.3.e.011
M. Weiser*, N. Werbeloff, G. Lubin, M. Shmushkevitz, A. Afek, M. Barchana, M. Davidson, Israel
 

P.3.e.012  How is family burden correlated to the patients’ symptoms, function, quality of life and attitude to medication?  Paper: P.3.e.012
F. Hjärthag*, L. Helldin, T. Norlander, Sweden
 

P.3.e.013  Long-term efficacy of repetitive TMS in the treatment of negative symptoms of schizophrenia  Paper: P.3.e.013
R. Prikryl*, L. Ustohal, T. Kasparek, S. Venclikova, H. Kucerova, E. Ceskova, Czech Republic
 

P.3.e.014  Attitudes toward medication among patients with schizophrenia  Paper: P.3.e.014
H. Olsson*, S. Stockman, Sweden
 

P.3.e.015  Psychometric proprieties from the French translation of the "Medication adherence rating scale" (MARS)  Paper: P.3.e.015
D. Misdrahi*, H. Verdoux, C. Lançon, L. Basuyau, M. Robin, F. Baylé, France
 

P.3.e.017  Biomarkers of oxidative stress in chronically medicated patients, treated with conventional and atypical antipsychotics  Paper: P.3.e.017
K. Kosma*, A. Sianni, K. Liatsos, A. Kontoangelos, C. Leotsakou, A. Kalogeropoulou, Greece
 

P.3.e.018  Antipsychotic preparation and schizophrenia relapse risk: a one-year survey in a naturalistic setting  Paper: P.3.e.018
J.C. Leuvennink*, D.J. Hall, K. Frew, United Kingdom
 

P.3.e.019  COMT genotype in schizophrenia: cognitive performance and brain circuits  Paper: P.3.e.019
P. Lopez-Garcia*, L. Young, M.D. Galvez, P. Molero, F. Ortuño, Spain
 

P.3.e.020  Acute agitation, psychotic symptoms and use of neuroleptics: a study of pre-hospital management  Paper: P.3.e.020
P. Tonn*, S.C. Reuter, N. Gerlach, N. Dahmen, Germany
 

P.3.e.021  Psychopharmacological treatment in catatonic schizophrenia  Paper: P.3.e.021
A. Ciobanu*, S. Mihalascu, D. Cristian, Romania
 

P.3.e.301  Sleep disturbance in schizophrenic inpatients
O. Dimova*, V. Filovska, M.J. Kujundziska, Macedonia
 

12:00-14:00
P.3.f:  Psychotic disorders and antipsychotics - Other (basic)
Poster area

P.3.f.001  Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?  Paper: P.3.f.001
D. Koethe*, A. Giuffrida, D. Schreiber, M. Hellmich, F. Schultze-Lutter, S. Ruhrmann, J. Klosterkoetter, D. Piomelli, F.M. Leweke, Germany
 

P.3.f.002  CNS infections during childhood and risk for schizophrenia: a case control study  Paper: P.3.f.002
D. Halperin*, M. Davidson, N. Werbeloff, R. Yoffe, A. Levine, G. Livni, M. Weiser, Israel
 

P.3.f.003  Dysfunctional gamma-band activity during the processing of facial structure in schizophrenia patients  Paper: P.3.f.003
S.H. Lee*, E.Y. Kim, S.R. Kim, Y.M. Park, H. Che, C.H. Im, South-Korea
 

P.3.f.004  Total antioxidant status, malondialdehyde and reduced glutathione serum levels in chronic paranoid schizophrenia  Paper: P.3.f.004
A.L. Morera*, A. Intxausti, P. Abreu-Gonzalez, M. Henry, A. Orozco-Sanmartin, E. Diaz-Mesa, Spain
 

P.3.f.005  A2A-adenosine, D2-dopamine and CB1-cannabinoid receptors in postmortem prefrontal cortex of schizophrenics  Paper: P.3.f.005
L. Urigüen, M.J. García-Fuster, L.F. Callado, B. Morentin, R. La Harpe, V. Casadó, C. Lluis, R. Franco, J.A. García-Sevilla, J.J. Meana*, Spain
 

P.3.f.006  Neonatal administration of HIV-1 proteins alters behaviour and NMDA receptor binding in the adult rat brain  Paper: P.3.f.006
H.B. Tejkalová*, T. Ruml, M. Rumlová, J. Klaschka, J. Myslivecek, F. Stastny, Czech Republic
 

12:00-14:00
P.5.a:  Dementia and neurological disorders - Dementia disorders (clinical)
Poster area

P.5.a.001  The grading systems of the korean long-term care system in the elderly with dementia; the 2nd pilot project  Paper: P.5.a.001
N. Hong*, B.K. Yeon, South-Korea
 

P.5.a.002  The correlation between caregiver's personality traits and caregiver burden in dementia  Paper: P.5.a.002
Y. Choi*, M.J. Kim, South-Korea
 

P.5.a.003  Risperidone vs. haloperidole in treatment of delirium superimposed on dementia  Paper: P.5.a.003
G. Djokic*, N. Zivkovic, D. Pavicevic, D. Lazic, K. Djokic, V. Marjanovic, Serbia
 

View last minute changes
P.5.a.004  Efficacy of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis  Paper: P.5.a.004
C. Kani*, K. Papanikolaou, A. Pehlivanidis, Z. Papadopoulou-Daifoti, Greece
C. Kani* will be replaced by A. Pehlivanidis
 

View last minute changes
P.5.a.005  Efficacy of cholinesterase inhibitors and memantine in Alzheimer's disease: a meta-analysis  Paper: P.5.a.005
C. Kani*, K. Papanikolaou, A. Pehlivanidis, Z. Papadopoulou-Daifoti, Greece
C. Kani* will be replaced by A. Pehlivanidis
 

P.5.a.006  Safety comparison of once-daily versus twice-daily memantine for the treatment of Alzheimer’s patients: a pooled analysis  Paper: P.5.a.006
R. Jones*, United Kingdom
 

P.5.a.007  Memantine decreases, and prevents the emergence of, key behavioural symptoms of Alzheimer’s disease  Paper: P.5.a.007
D. Wilkinson*, S. Gauthier, B. Rive, United Kingdom
 

P.5.a.008  Yearly longitudinal prospective healthcare costs of Alzheimer disease in routine medical practice: a Spanish perspective  Paper: P.5.a.008
I. Rabasa*, A. Coduras, A. Frank, F. Bermejo, S. López-Pousa, J.M. López-Arrieta, J. Del Llano, T. León, J. Rejas, Spain
 

P.5.a.009  Divalproex sodium in behavioural disturbances in dementia: clinical effectiveness  Paper: P.5.a.009
V. Fricchione Parise*, Italy
 

P.5.a.301  The factors that affect on activities of daily living among psychiatric disorders in elderly patients
B.H. Koo*, J.K. Sagong, J.H. Lee, South-Korea
 

P.5.a.302  Psychiatric medication for elderly people with mental illness
M. Mosescu*, A. Stefanescu, Romania
 

P.5.a.303  Safety and efficacy of tarenflurbil in mild Alzheimer’s disease: results from an 18-month, multicentre phase III trial
R.C. Green*, L.S. Schneider, T. Johnson, S.B. Hendrix, K.H. Zavitz, E. Swabb, USA
 

12:00-14:00
P.5.b:  Dementia and neurological disorders - Dementia disorders (basic)
Poster area

P.5.b.001  The implication of oxidative stress in a rat model of Parkinson’s disease  Paper: P.5.b.001
M. Padurariu*, L. Hritcu, A. Ciobica, V. Artenie, Romania
 

P.5.b.002  The neuroprotective effect of apoliporotein E on the oxidative stress in alzheimer's disease  Paper: P.5.b.002
W. Cho*, H. Yoon, South-Korea
<